Thiazolidinedione safety

Effects of Intensive Glucose Lowering in Type 2 Diabetes

(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888 · see citing works

Glucose control and vascular complications in veterans with type 2 diabetes

Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762 · see citing works

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · see citing works

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129 · see citing works

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834 · see citing works

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962 · see citing works

A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease

(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805796 · Cited by 1,939 · see citing works

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

(2006) · The Lancet · doi:10.1016/s0140-6736(06)69420-8 · Cited by 1,706 · see citing works

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

Home, P. D., Pocock, S. J., Beck-Nielsen, H., Curtis, P. S., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60953-3 · Cited by 1,393 · see citing works

Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ by Cdk5

Choi, J. H., Banks, A. S., Estall, J. L., Kajimura, S., Boström, P., Laznik, D., Ruas, J. L., Chalmers, M. J., Kamenecka, T. M., Blüher, M., et al. (2010) · Nature · doi:10.1038/nature09291 · Cited by 886 · see citing works

Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure

Nesto, R. W., Bell, D. S. H., Bonow, R. O., Fonseca, V. A., Grundy, S. M., Horton, E. S., Winter, M. L., Porte, D., Semenkovich, C. F., Smith, S. E., et al. (2003) · Circulation · doi:10.1161/01.cir.0000103683.99399.7e · Cited by 831 · see citing works

A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia

Goldberg, R. B., Kendall, D. M., Deeg, M. A., Buse, J. B., Zagar, A. J., Pinaire, J. A., Tan, M. H., Khan, M. A., Perez, A. T., Jacober, S. J., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1547 · Cited by 790 · see citing works

Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients

Miyazaki, Y., Mahankali, A., Matsuda, M., Mahankali, S., Hardies, J., Cusi, K., Mandarino, L. J., & DeFronzo, R. A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.6.8567 · Cited by 726 · see citing works

Business Information

Rodbard, H. W., Blonde, L., Ss, B., Brett, E. M., Cobin, R. H., Handelsman, Y., Hellman, R., Jellinger, P. S., Jovanovic, L. G., Levy, P., et al. (2007) · Endocrine Practice · doi:10.4158/ep.13.s1.1 · Cited by 693 · see citing works

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

Aronoff, S., Rosenblatt, S., Braithwaite, S. S., Egan, J. W., Mathisen, A. L., & Schneider, R. (2000) · Diabetes Care · doi:10.2337/diacare.23.11.1605 · Cited by 626 · see citing works

Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone

Lewis, J. D., Ferrara, A., Peng, T., Hedderson, M., Bilker, W. B., Quesenberry, C. P., Vaughn, D. J., Nessel, L., Selby, J., & Strom, B. L. (2011) · Diabetes Care · doi:10.2337/dc10-1068 · Cited by 625 · see citing works

Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption

Guan, Y., Hao, C., Cha, D. R., Rao, R., Lu, W., Kohan, D. E., Magnuson, M. A., Redha, R., Zhang, Y., & Breyer, M. D. (2005) · Nature Medicine · doi:10.1038/nm1278 · Cited by 608 · see citing works

Rosiglitazone Revisited

Nissen, S. E., & Wolski, K. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.207 · Cited by 590 · see citing works

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

Loke, Y. K., Singh, S., & Furberg, C. D. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080486 · Cited by 553 · see citing works

Effect of Muraglitazar on Death and Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus

Nissen, S. E. (2005) · JAMA · doi:10.1001/jama.294.20.joc50147 · Cited by 552 · see citing works

Treatment of insulin resistance with peroxisome proliferator–activated receptor γ agonists

Olefsky, J. M. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10843 · Cited by 536 · see citing works

Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated With Rosiglitazone or Pioglitazone

Graham, D. J., Ouellet‐Hellstrom, R., MaCurdy, T. E., Ali, F. N., Sholley, C., Worrall, C. M., & Kelman, J. A. (2010) · JAMA · doi:10.1001/jama.2010.920 · Cited by 512 · see citing works

Bone Is a Target for the Antidiabetic Compound Rosiglitazone

Rzońca, S., Suva, L. J., Gaddy, D., Montague, D. C., & Lecka‐Czernik, B. (2003) · Endocrinology · doi:10.1210/en.2003-0746 · Cited by 455 · see citing works

Rosiglitazone Causes Bone Loss in Mice by Suppressing Osteoblast Differentiation and Bone Formation

Ali, A., Weinstein, R. S., Stewart, S. A., PARFITT, A. M., Manolagas, S. C., & Jilka, R. L. (2005) · Endocrinology · doi:10.1210/en.2004-0735 · Cited by 444 · see citing works

The Effect of Pioglitazone on Recurrent Myocardial Infarction in 2,445 Patients With Type 2 Diabetes and Previous Myocardial Infarction

Erdmann, E., Dormandy, J., Charbonnel, B. H., Massi‐Benedetti, M., Moules, I. K., & Skene, A. M. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.12.048 · Cited by 377 · see citing works

Thiazolidinediones and Cardiovascular Outcomes in Older Patients With Diabetes

Lipscombe, L. L., Gomes, T., Lévesque, L. E., Hux, J. E., Juurlink, D. N., & Alter, D. A. (2007) · JAMA · doi:10.1001/jama.298.22.2634 · Cited by 345 · see citing works

Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells.

Gimble, J. M., Robinson, C. E., Wu, X., Kelly, K. A., Rodriguez, B., Kliewer, S. A., Lehmann, J. M., & Morris, D. C. (1996) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09536-7 · Cited by 295 · see citing works

Thiazolidinediones in Type 2 Diabetes Mellitus

Diamant, M., & Heine, R. J. (2003) · Drugs · doi:10.2165/00003495-200363130-00004 · Cited by 278 · see citing works

Efficacy and Safety of Pioglitazone Versus Metformin in Patients with Type 2 Diabetes Mellitus: A Double-Blind, Randomized Trial

Schernthaner, G., Matthews, D. R., Charbonnel, B. H., Markolf Hanefeld, E., & Brunetti, P. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030861 · Cited by 268 · see citing works

Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes

Dormandy, J., Bhattacharya, M., & van Troostenburg, A. (2009) · Drug Safety · doi:10.2165/00002018-200932030-00002 · Cited by 227 · see citing works

The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus

Rosenblatt, S., Miskin, B., Glazer, N. B., PRINCE, M. J., & Robertson, K. E. (2001) · Coronary Artery Disease · doi:10.1097/00019501-200108000-00011 · Cited by 219 · see citing works

Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study

Henry, R. R., Lincoff, A. M., Mudaliar, S. R. D., Rabbia, M. A., Chognot, C., & Herz, M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60870-9 · Cited by 205 · see citing works

The Rosiglitazone Story — Lessons from an FDA Advisory Committee Meeting

Rosen, C. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmp078167 · Cited by 201 · see citing works

Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis

Sorocéanu, M. A., Miao, D., Bai, X., Su, H., Goltzman, D., & Karaplis, A. C. (2004) · Journal of Endocrinology · doi:10.1677/joe.1.05723 · Cited by 199 · see citing works

Rosiglitazone and Cardiovascular Risk

Psaty, B. M., & Furberg, C. D. (2007) · New England Journal of Medicine · doi:10.1056/nejme078099 · Cited by 180 · see citing works

Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial

Smith, S. R., de Jonge, L., Volaufova, J., Li, Y., Xie, H., & Bray, G. A. (2005) · Metabolism · doi:10.1016/j.metabol.2004.07.008 · Cited by 176 · see citing works

Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study

Juurlink, D. N., Gomes, T., Lipscombe, L. L., Austin, P. C., Hux, J. E., & Mamdani, M. (2009) · BMJ · doi:10.1136/bmj.b2942 · Cited by 170 · see citing works

The pharmacokinetics of pioglitazone in patients with impaired renal function

Budde, K., Neumayer, H., Fritsche, L., Sułowicz, W., Stompór, T. P., & Eckland, D. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01785.x · Cited by 142 · see citing works

Pioglitazone is Metabolised by CYP2C8 and CYP3A4 in vitro : Potential for Interactions with CYP2C8 Inhibitors

Jaakkola, T., Laitila, J., Neuvonen, P. J., & Backman, J. T. (2006) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2006.pto_437.x · Cited by 142 · see citing works

DIABETIC MACULAR EDEMA ASSOCIATED WITH GLITAZONE USE

Ryan, E. H., Han, D. P., Ramsay, R. C., Cantrill, H. L., Bennett, S. R., Dev, S., & Williams, D. F. (2006) · Retina · doi:10.1097/00006982-200605000-00011 · Cited by 137 · see citing works

Benzoyl 2-methyl indoles as selective PPARγ modulators

Acton, J. J., Black, R. M., Jones, A. B., Moller, D. E., Colwell, L. F., Doebber, T. W., MacNaul, K. L., Berger, J. P., & Wood, H. B. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.10.068 · Cited by 130 · see citing works

A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus

Herz, M., Johns, D., Reviriego, J., Grossman, L. D., Godin, C., Durán, S., Hawkins, F. G., Lochnan, H. A., Escobar‐Jiménez, F., Hardin, P. A., et al. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80068-1 · Cited by 130 · see citing works

Revisiting the Rosiglitazone Story — Lessons Learned

Rosen, C. J. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1008233 · Cited by 123 · see citing works

Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone

Jaakkola, T., Backman, J. T., Neuvonen, M., & Neuvonen, P. J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.12.266 · Cited by 118 · see citing works

Comparison of Cardiovascular Outcomes in Elderly Patients With Diabetes Who Initiated Rosiglitazone vs Pioglitazone Therapy

Winkelmayer­, W. C., Setoguchi, S., Levin, R., & Solomon, D. H. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.21.2368 · Cited by 115 · see citing works

Trimethoprim and the CYP2C8*3 Allele Have Opposite Effects on the Pharmacokinetics of Pioglitazone

Tornio, A., Niemi, M., Neuvonen, P. J., & Backman, J. T. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.018010 · Cited by 114 · see citing works

Coronary heart disease outcomes in patients receiving antidiabetic agents

McAfee, A. T., Koro, C. E., Landon, J. E., Ziyadeh, N. J., & Walker, A. M. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1443 · Cited by 108 · see citing works

Glycemic control with Glyburide/Metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial

DAILEY, G. E., Noor, M. A., Park, J.-S., BRUCE, S. R., & Fiedorek, F. T. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.07.022 · Cited by 107 · see citing works

Association between serious ischemic cardiac outcomes and medications used to treat diabetes

Margolis, D. J., Hoffstad, O., & Strom, B. L. (2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1630 · Cited by 104 · see citing works

Glitazone Use Associated with Diabetic Macular Edema

Fong, D. S., & Contreras, R. (2009) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2008.10.016 · Cited by 102 · see citing works

Thiazolidinediones, peroxisome proliferator-activated receptor γ agonists, regulate endothelial cell growth and secretion of vasoactive peptides

Fukunaga, Y., Itoh, H., Doi, K., Tanaka, T., Yamashita, J. K., Chun, T., Inoue, M., Masatsugu, K., Sawada, N., Saito, T., et al. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(01)00430-0 · Cited by 100 · see citing works

Evolution of Peroxisome Proliferator-Activated Receptor Agonists

Chang, F., Jaber, L. A., Berlie, H. D., & O’Connell, M. B. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1k013 · Cited by 100 · see citing works

Effects of the Peroxisomal Proliferator-Activated Receptor-γ Agonist Pioglitazone on Renal and Hormonal Responses to Salt in Healthy Men

Zanchi, A., Chioléro, A., Maillard, M. P., Nussberger, J., Brunner, H., & Burnier, M. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031526 · Cited by 97 · see citing works

Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: Results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study

Mattoo, V., Eckland, D. J. A., Widel, M., Durán, S., Fajardo, C., Strand, J., Knight, D., Grossman, L. D., Oakley, D., & Tan, M. H. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.05.005 · Cited by 94 · see citing works

Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes

Belcher, G., Lambert, C., Edwards, G., Urquhart, R., & Matthews, D. R. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2005.02.011 · Cited by 90 · see citing works

Effect of rifampicin on the pharmacokinetics of pioglitazone

Jaakkola, T., Backman, J. T., Neuvonen, M., Laitila, J., & Neuvonen, P. J. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02515.x · Cited by 89 · see citing works

Reduction in Hematocrit and Hemoglobin Following Pioglitazone Treatment is not Hemodilutional in Type II Diabetes Mellitus

Berria, R., Glass, L. C., Mahankali, A., Miyazaki, Y., Monroy, A., Filippis, E. D., Cusi, K. J., Cersósimo, E., DeFronzo, R. A., & Gastaldelli, A. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100146 · Cited by 85 · see citing works

A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes

Gerrits, C. M., Bhattacharya, M., Manthena, S. R., Baran, R. W., Perez, A., & Kupfer, S. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1470 · Cited by 82 · see citing works

Rapid Identification of Myocardial Infarction Risk Associated With Diabetes Medications Using Electronic Medical Records

Brownstein, J. S., Murphy, S. N., Goldfine, A. B., Grant, R. W., Sordo, M., Gainer, V. S., Colecchi, J., Dubey, A. K., Nathan, D. M., GLASER, J. P., et al. (2009) · Diabetes Care · doi:10.2337/dc09-1506 · Cited by 82 · see citing works

Cardiac safety profile of rosiglitazone

Mannucci, E., Monami, M., Bari, M. D., Lamanna, C., Gori, F., Gensini, G. F., & Marchionni, N. (2009) · International Journal of Cardiology · doi:10.1016/j.ijcard.2009.01.064 · Cited by 72 · see citing works

Oral Antidiabetic Agents in Pregnancy and Lactation: A Paradigm Shift?

Feig, D. S., BRIGGS, G. G., & Koren, G. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1k045 · Cited by 72 · see citing works

Selective modulation of promoter recruitment and transcriptional activity of PPARγ

Sears, D. D., Hsiao, A., Ofrecio, J. M., Chapman, J., He, W., & Olefsky, J. M. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.10.057 · Cited by 70 · see citing works

Effects of 1 Year of Treatment with Pioglitazone or Rosiglitazone Added to Glimepiride on Lipoprotein (a) and Homocysteine Concentrations in Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome: A Multicenter, Randomized, Double-Blind, Controlled Clinical Trial

Derosa, G., Cicero, A. F. G., D’Angelo, A., Gaddi, A. V., Ciccarelli, L., Piccinni, M. N., SALVADEO, S. A. T., PRICOLO, F., Ferrari, I., Gravina, A., et al. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.05.012 · Cited by 67 · see citing works

Case series of liver failure associated with rosiglitazone and pioglitazone

Floyd, J. S., Barbehenn, E. K., Lurie, P. G., & Wolfe, S. M. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1804 · Cited by 63 · see citing works

Placental transfer of rosiglitazone in the first trimester of human pregnancy

Chan, L. Y.-S., Yeung, J. H. K., & Lau, T. K. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.10.045 · Cited by 63 · see citing works

Effect of gemfibrozil on the pharmacokinetics of pioglitazone

Deng, L., Wang, F., & Huan-de, L. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0042-6 · Cited by 59 · see citing works

Discovery and development of selective PPARγ modulators as safe and effective antidiabetic agents

Doshi, L. S., Brahma, M. K., Bahirat, U. A., Dixit, A. V., & Nemmani, K. V. S. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543781003640169 · Cited by 59 · see citing works

The Oral Insulin Sensitizer, Thiazolidinedione, Increases Plasma Vascular Endothelial Growth Factor in Type 2 Diabetic Patients

Baba, T., Shimada, K., Neugebauer, S., Yamada, D., Hashimoto, S., & Watanabe, T. (2001) · Diabetes Care · doi:10.2337/diacare.24.5.953 · Cited by 58 · see citing works

Liver Safety in Patients with Type 2 Diabetes Treated with Pioglitazone

Tolman, K. G., Freston, J. W., Kupfer, S., & Pérez, A. (2009) · Drug Safety · doi:10.2165/11316510-000000000-00000 · Cited by 55 · see citing works

Diabetes drug pioglitazone (Actos): risk of fracture

Meymeh, R. H., & Wooltorton, E. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.071177 · Cited by 52 · see citing works

Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy

Berhanu, P., Pérez, A., & Yu, S. S. (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00633.x · Cited by 52 · see citing works

Pioglitazone as adjunctive therapy in adolescents with type 1 diabetes

Zdravković, V., Hamilton, J. K., Daneman, D., & Cummings, E. A. (2006) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2006.08.049 · Cited by 50 · see citing works

Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin–angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20)

Erdmann, E., Spanheimer, R. G., Charbonnel, B. H., & on behalf of the PROactive Study Investigators (2010) · Journal of Diabetes · doi:10.1111/j.1753-0407.2010.00082.x · Cited by 46 · see citing works

Successful pregnancies treated with pioglitazone in infertile patients with polycystic ovary syndrome

Ota, H., Goto, T., Yoshioka, T., & Ohyama, N. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.01.117 · Cited by 43 · see citing works

Rosiglitazone and Cardiovascular Risk

Bracken, M. B. (2007) · New England Journal of Medicine · doi:10.1056/nejmc071602 · Cited by 42 · see citing works

The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: A retrospective cohort study using a US health insurance database

Ziyadeh, N. J., McAfee, A. T., Koro, C. E., Landon, J. E., & Chan, K. A. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.11.003 · Cited by 41 · see citing works

Urothelial Carcinogenesis in the Urinary Bladder of Rats Treated with Naveglitazar, a γ-dominant PPAR α/γ Agonist: Lack of Evidence for Urolithiasis as an Inciting Event

Long, G. G., Reynolds, V. L., López‐Martinez, A., Ryan, T. E., White, S. L., & Eldridge, S. R. (2008) · Toxicologic Pathology · doi:10.1177/0192623307311757 · Cited by 40 · see citing works

Pioglitazone is Effective Therapy for Elderly Patients with Type 2 Diabetes Mellitus

Rajagopalan, R., Pérez, A., Ye, Z., Khan, M. A., & Murray, F. T. (2004) · Drugs & Aging · doi:10.2165/00002512-200421040-00004 · Cited by 39 · see citing works

Effects of high dose aleglitazar on renal function in patients with type 2 diabetes

Herz, M., Gaspari, F., Perico, N., Viberti, G. C., Urbanowska, T., Rabbia, M. A., & Kirk, D. A. W. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.08.037 · Cited by 39 · see citing works

Thiazolidinedione Safety and Efficacy in Ambulatory Patients Receiving Hemodialysis

Manley, H. J., & Allcock, N. M. (2003) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.7.861.32727 · Cited by 34 · see citing works

New life for antidiabetic drugs

Houtkooper, R. H., & Auwerx, J. H. (2010) · Nature · doi:10.1038/466443a · Cited by 29 · see citing works

Comparative Effectiveness of Pioglitazone and Rosiglitazone in Type 2 Diabetes, Prediabetes,and the Metabolic Syndrome: A Meta-Analysis

Norris, S. L., Carson, S., & Roberts, C. (2007) · Current Diabetes Reviews · doi:10.2174/157339907780598216 · Cited by 29 · see citing works

Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis

Abe, M., Okada, K., Maruyama, T., Maruyama, N., Soma, M., & Matsumoto, K. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.495119 · Cited by 25 · see citing works

Fracture risk a class effect of thiazolidinediones in women

Short, R. (2007) · BMJ · doi:10.1136/bmj.39154.373889.db · Cited by 24 · see citing works

Efficacy of pioglitazone on type 2 diabetic patients with hemodialysis

Abe, M., Kikuchi, F., Okada, K., Kaizu, K., & Matsumoto, K. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.01.028 · Cited by 15 · see citing works

Clinical evaluation of pioglitazone in patients with type 2 diabetes using α‐glucosidase inhibitor and examination of its efficacy profile

Hayashi, Y., Miyachi, N., Takeuchi, T., Takeuchi, Y., Kamiya, F., Kato, T., Imaeda, K., Okayama, N., Shimizu, M., & Itoh, M. (2003) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2003.00244.x · Cited by 12 · see citing works

The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: A post hoc analysis of four randomized trials

Rajagopalan, R., Xu, Y., & Abbadessa, M. (2006) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2006.06.003 · Cited by 11 · see citing works

Suspected Suppression of the INR by Thiazolidinediones: Interaction Between Warfarin and TZDs

Hoffmann, T. K., Parker, D., Buch, H. A., & Balusu, P. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1g474 · Cited by 6 · see citing works

Long-term Risk of Cardiovascular Events With Rosiglitazone: A Meta-analysis

Singh, S., Loke, Y. K., & Furberg, C. D. (2007) · JAMA · doi:10.1001/jama.298.10.1189 · Cited by 5 · see citing works

PPARγ signaling and metabolism: the good, the bad and the future

Ahmadian, M., Suh, J. M., Hah, N., Liddle, C., Atkins, A. R., Downes, M., & Evans, R. M. (2013) · Nature Medicine · doi:10.1038/nm.3159 · Cited by 2,016 · see citing works

Metabolic Flexibility as an Adaptation to Energy Resources and Requirements in Health and Disease

Smith, R. L., Soeters, M. R., Wüst, R. C. I., & Houtkooper, R. H. (2018) · Endocrine Reviews · doi:10.1210/er.2017-00211 · Cited by 787 · see citing works

Mechanisms of Obesity-Induced Inflammation and Insulin Resistance: Insights into the Emerging Role of Nutritional Strategies

McArdle, M. A., Finucane, O. M., Connaughton, R. M., McMorrow, A. M., & Roche, H. M. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00052 · Cited by 532 · see citing works

Pharmacological approaches to restore mitochondrial function

Andreux, P. A., Houtkooper, R. H., & Auwerx, J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4023 · Cited by 383 · see citing works

Repairing mitochondrial dysfunction in disease

Sorrentino, V., Menzies, K. J., & Auwerx, J. (2018) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104908 · Cited by 337 · see citing works

Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention

Gottwald‐Hostalek, U., Gwilt, M., & Hildemann, S. K. (2015) · Drugs · doi:10.1007/s40265-015-0416-8 · Cited by 278 · see citing works

Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis: Recommendations from PancreasFest 2012

Rickels, M. R., Bellin, M., Toledo, F. G. S., Robertson, R. P., Andersen, D. K., Chari, S. T., Brand, R., Frulloni, L., Anderson, M. A., & Whitcomb, D. C. (2013) · Pancreatology · doi:10.1016/j.pan.2013.05.002 · Cited by 249 · see citing works

Pioglitazone use and risk of bladder cancer: Population based cohort study

Tuccori, M., Filion, K. B., Yin, H., Yu, O. H., Platt, R. W., & Azoulay, L. (2016) · BMJ · doi:10.1136/bmj.i1541 · Cited by 237 · see citing works

PPARs and Metabolic Disorders Associated with Challenged Adipose Tissue Plasticity

Corrales, P., Vidal‐Puig, A., & Medina‐Gómez, G. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072124 · Cited by 185 · see citing works

Physiological functions of peroxisome proliferator-activated receptor β

Neels, J. G., & Grimaldi, P. A. (2014) · Physiological Reviews · doi:10.1152/physrev.00027.2013 · Cited by 161 · see citing works

Primary cicatricial alopecia

Bolduc, C., Sperling, L. C., & Shapiro, J. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.09.058 · Cited by 135 · see citing works

Revisiting PPARγ as a target for the treatment of metabolic disorders

Choi, S., Park, J., & Choi, J. H. (2014) · BMB Reports · doi:10.5483/bmbrep.2014.47.11.174 · Cited by 133 · see citing works

Genetic and epigenetic control of metabolic health

Schwenk, R. W., Vogel, H., & Schürmann, A. (2013) · Molecular Metabolism · doi:10.1016/j.molmet.2013.09.002 · Cited by 132 · see citing works

Learning from berberine: Treating chronic diseases through multiple targets

Yao, J., Kong, W., & Jiang, J. (2013) · Science China Life Sciences · doi:10.1007/s11427-013-4568-z · Cited by 118 · see citing works

Berberine modulates deacetylation of PPARγ to promote adipose tissue remodeling and thermogenesis via AMPK/SIRT1 pathway

Xu, Y., Yu, T., Ma, G., Zheng, L., Jiang, X., Yang, F., Wang, Z., Li, N., He, Z., Song, X., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.62556 · Cited by 110 · see citing works

Efficient Targeting of Adipose Tissue Macrophages in Obesity with Polysaccharide Nanocarriers

Ma, L., Cross, T.-W., Wallig, M. A., Dobrucki, I. T., Dobrucki, L. W., Nelson, E. R., Swanson, K. S., & Smith, A. M. (2016) · ACS Nano · doi:10.1021/acsnano.6b02878 · Cited by 113 · see citing works

The Role of Vitamin D Oral Supplementation in Insulin Resistance in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Łagowska, K., Bajerska, J., & Jamka, M. (2018) · Nutrients · doi:10.3390/nu10111637 · Cited by 113 · see citing works

Preliminary evidence that cinnamon improves menstrual cyclicity in women with polycystic ovary syndrome: a randomized controlled trial

Kort, D. H., & Lobo, R. A. (2014) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2014.05.009 · Cited by 111 · see citing works

New forms of insulin and insulin therapies for the treatment of type 2 diabetes

Cahn, A., Miccoli, R., Dardano, A., & Prato, S. D. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00097-2 · Cited by 107 · see citing works

Telmisartan ameliorates glutamate-induced neurotoxicity: Roles of AT1 receptor blockade and PPARγ activation

Wang, J., Pang, T., Hafko, R., Benický, J., Sánchez-Lemus, E., & Saavedra, J. M. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.11.022 · Cited by 107 · see citing works

Beiging of white adipose tissue as a therapeutic strategy for weight loss in humans

Thyagarajan, B., & Foster, M. T. (2017) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2017-0016 · Cited by 106 · see citing works

The effect of peroxisome proliferator-activated receptor-γ ligands on in vitro and in vivo models of COPD

Lea, S., Plumb, J., Metcalfe, H. J., Spicer, D., Woodman, P., Fox, J. C., & Singh, D. (2013) · European Respiratory Journal · doi:10.1183/09031936.00187812 · Cited by 105 · see citing works

Treatment of type 2 diabetes mellitus in the elderly

Yakaryılmaz, F. D., & Öztürk, Z. A. (2017) · World Journal of Diabetes · doi:10.4239/wjd.v8.i6.278 · Cited by 104 · see citing works

Neuroprotective effects of oleic acid in rodent models of cerebral ischaemia

Song, J., Kim, Y., Lee, D. H., Lee, S. H., Park, H. J., Lee, D., & Kim, H. (2019) · Scientific Reports · doi:10.1038/s41598-019-47057-z · Cited by 101 · see citing works

Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013

Schernthaner, G., Currie, C. J., & Schernthaner, G.-H. (2013) · Diabetes Care · doi:10.2337/dcs13-2031 · Cited by 100 · see citing works

Metformin and metabolic diseases: a focus on hepatic aspects

Zheng, J., Woo, S., Hu, X., Botchlett, R. E., Chen, L., Huo, Y., & Wu, C. (2015) · Frontiers of Medicine · doi:10.1007/s11684-015-0384-0 · Cited by 99 · see citing works

Adipocyte-specific loss of PPARγ attenuates cardiac hypertrophy

Fang, X., Stroud, M. J., Ouyang, K., Li, F., Zhang, J., Dalton, N. D., Gu, Y., Wu, T., Peterson, K. L., Huang, H., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.89908 · Cited by 97 · see citing works

Anti-diabetic rosiglitazone remodels the adipocyte transcriptome by redistributing transcription to PPARγ-driven enhancersPreprint

Step, S. E., Lim, H., Marinis, J. M., Prokesch, A., Steger, D. J., You, S.-H., Won, K., & Lazar, M. A. (2014) · Genes & Development · doi:10.1101/gad.237628.114 · Cited by 97 · see citing works

The role of PPAR γ‐mediated signalling in skin biology and pathology: new targets and opportunities for clinical dermatology

Ramot, Y., Mastrofrancesco, A., Camera, E., Desreumaux, P., Paus, R., & Picardo, M. (2015) · Experimental Dermatology · doi:10.1111/exd.12647 · Cited by 95 · see citing works

Management of pancreatogenic diabetes: challenges and solutions

Makuc, J. (2016) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s99701 · Cited by 84 · see citing works

Maintenance of Kidney Metabolic Homeostasis by PPAR Gamma

Corrales, P., Izquierdo‐Lahuerta, A., & Medina‐Gómez, G. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072063 · Cited by 77 · see citing works

Overview of clinically approved oral antidiabetic agents for the treatment of type 2 diabetes mellitus

He, Z., Zhou, Z., Yang, Y., Yang, T., Pan, S., Qiu, J., & Zhou, S. (2014) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12332 · Cited by 74 · see citing works

Thiazolidinedione-Induced Fluid Retention: Recent Insights into the Molecular Mechanisms

Bełtowski, J., Rachańczyk, J., & Włodarczyk, M. (2013) · PPAR Research · doi:10.1155/2013/628628 · Cited by 74 · see citing works

Modulation of Peroxisome Proliferator-Activated Receptor gamma (PPAR γ) by Conjugated Fatty Acid in Obesity and Inflammatory Bowel Disease

Yuan, G., Chen, X., & Li, D. (2015) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf505050c · Cited by 76 · see citing works

Paracrine FGFs target skeletal muscle to exert potent anti-hyperglycemic effects

Lei, Y., Wang, L., Guo, K., Hou, Y., Li, N., Wang, S., Liu, X., Zhao, Q., Zhou, J., Zhao, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27584-y · Cited by 73 · see citing works

Type-3c Diabetes Mellitus, Diabetes of Exocrine Pancreas - An Update

Bhattamisra, S. K., Siang, T. C., Rong, C. Y., Annan, N. C., Sean, E. H. Y., Xi, L. W., Lyn, O. S., Liew, H. S., Choudhury, H., Pandey, M., et al. (2019) · Current Diabetes Reviews · doi:10.2174/1573399815666190115145702 · Cited by 72 · see citing works

The Scavenger Receptor CD36 Downmodulates the Early Inflammatory Response while Enhancing Bacterial Phagocytosis during Pneumococcal Pneumonia

Sharif, O., Matt, U., Saluzzo, S., Lakovits, K., Haslinger, I., Furtner, T., Doninger, B., & Knapp, S. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202270 · Cited by 70 · see citing works

Senescence Alters PPARγ (Peroxisome Proliferator–Activated Receptor Gamma)-Dependent Fatty Acid Handling in Human Adipose Tissue Microvascular Endothelial Cells and Favors Inflammation

Briot, A., Decaunes, P., Volat, F., Belles, C., Coupaye, M., Ledoux, S., & Bouloumié, A. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.310797 · Cited by 67 · see citing works

Regulator of G protein signaling 5 is a determinant of gestational hypertension and preeclampsia

Holobotovskyy, V., Chong, Y. S., Burchell, J. T., He, B., Phillips, M. R., Leader, L. R., Murphy, T. V., Sandow, S. L., McKitrick, D. J., CHARLES, A. K., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa5038 · Cited by 64 · see citing works

Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options

Chiu, C., Du, Y., Ou, H., & Beverly, E. A. (2014) · Clinical Interventions in Aging · doi:10.2147/cia.s53482 · Cited by 62 · see citing works

Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease

Heebøll, S. (2014) · World Journal of Hepatology · doi:10.4254/wjh.v6.i4.188 · Cited by 60 · see citing works

Combating Obesity With Thermogenic Fat: Current Challenges and Advancements

Pan, R., Zhu, X., Maretich, P., & Chen, Y. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00185 · Cited by 60 · see citing works

Kdm2a deficiency in macrophages enhances thermogenesis to protect mice against HFD-induced obesity by enhancing H3K36me2 at the Pparg locus

Chen, L., Zhang, J., Zou, Y., Wang, F., Li, J., Sun, F., Luo, X., Zhang, M., Guo, Y., Yu, Q., et al. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-020-00714-7 · Cited by 58 · see citing works

New Insights into the Role of PPARγ in Skin Physiopathology

Briganti, S., Mosca, S., Nardo, A. D., Flori, E., & Ottaviani, M. (2024) · Biomolecules · doi:10.3390/biom14060728 · Cited by 59 · see citing works

Endothelial PPAR-γ provides vascular protection from IL-1β-induced oxidative stress

Mukohda, M., Stump, M., Ketsawatsomkron, P., Hu, C., Quelle, F. W., & Sigmund, C. D. (2015) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00490.2015 · Cited by 57 · see citing works

Purslane Extract and Glucose Homeostasis in Adults with Type 2 Diabetes: A Double-Blind, Placebo-Controlled Clinical Trial of Efficacy and Safety

Wainstein, J., Landau, Z., Dayan, Y. B., Jakubowicz, D. J., Grothe, T., Perrinjaquet-Moccetti, T., & Boaz, M. (2016) · Journal of Medicinal Food · doi:10.1089/jmf.2015.0090 · Cited by 56 · see citing works

Complications of Diabetes Therapy

Corathers, S. D., Peavie, S., & Salehi, M. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.06.005 · Cited by 58 · see citing works

A glimpse of the connection between PPARγ and macrophage

Yu, L., Gao, Y., Aaron, N., & Qiang, L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1254317 · Cited by 54 · see citing works

Delta-9-tetrahydrocannabinol protects against MPP+ toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis

Zeissler, M., Eastwood, J., McCorry, K., Hanemann, C. O., Zajicek, J., & Carroll, C. (2016) · Oncotarget · doi:10.18632/oncotarget.10314 · Cited by 54 · see citing works

δ-Tocotrienol, Isolated from Rice Bran, Exerts an Anti-Inflammatory Effect via MAPKs and PPARs Signaling Pathways in Lipopolysaccharide-Stimulated Macrophages

Shen, J., Yang, T., Xu, Y., Luo, Y., Zhong, X., Shi, L., Hu, T., Guo, T., Nie, Y., Luo, F., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103022 · Cited by 50 · see citing works

Sirtuins-Mediated System-Level Regulation of Mammalian Tissues at the Interface between Metabolism and Cell Cycle: A Systematic Review

Maissan, P., Mooij, E., & Barberis, M. (2021) · Biology · doi:10.3390/biology10030194 · Cited by 50 · see citing works

New Insights into the PPARγAgonists for the Treatment of Diabetic Nephropathy

Jia, Z., Sun, Y., Yang, G., Zhang, A., Huang, S., Heiney, K. M., & Zhang, Y. (2014) · PPAR Research · doi:10.1155/2014/818530 · Cited by 49 · see citing works

Pharmacogenomics and Pharmacogenetics of Thiazolidinediones: Role in Diabetes and Cardiovascular Risk Factors

Della‐Morte, D., Palmirotta, R., Rehni, A. K., Pastore, D., Capuani, B., Pacifici, F., Marchis, M. L. D., Dave, K. R., Bellia, A., Fogliame, G., et al. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.162 · Cited by 49 · see citing works

Aging-Associated Reductions in Lipolytic and Mitochondrial Proteins in Mouse Adipose Tissue Are Not Rescued by Metformin Treatment

Mennes, E., Dungan, C. M., Frendo‐Cumbo, S., Williamson, D. L., & Wright, D. C. (2013) · The Journals of Gerontology Series A · doi:10.1093/gerona/glt156 · Cited by 47 · see citing works

Activation of catalase by pioglitazone: Multiple spectroscopic methods combined with molecular docking studies

Yekta, R., Dehghan, G., Rashtbari, S., Sheibani, N., & Moosavi‐Movahedi, A. A. (2017) · Journal of Molecular Recognition · doi:10.1002/jmr.2648 · Cited by 45 · see citing works

PPAR‐γ – a possible drug target for complicated pregnancies

McCarthy, F. P., Delany, A. C., Kenny, L. C., & Walsh, S. K. (2012) · British Journal of Pharmacology · doi:10.1111/bph.12069 · Cited by 43 · see citing works

Taurine improves low‐level inorganic arsenic‐induced insulin resistance by activating PPARγ‐mTORC2 signalling and inhibiting hepatic autophagy

Gao, N., Yao, X., Jiang, L., Yang, L., Qiu, T., Wang, Z., Pei, P., Yang, G., Liu, X., & Sun, X. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27318 · Cited by 43 · see citing works

Fetuin-A downregulates adiponectin through Wnt-PPARγ pathway in lipid induced inflamed adipocyte

Agarwal, S., Chattopadhyay, M., Mukherjee, S., Dasgupta, S., Mukhopadhyay, S., & Bhattacharya, S. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.10.002 · Cited by 42 · see citing works

The metabolic vascular syndrome - guide to an individualized treatment

Hanefeld, M., Pistrosch, F., Bornstein, S. R., & Birkenfeld, A. L. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9345-4 · Cited by 41 · see citing works

Alterbrassicicene A, a Highly Transformed Fusicoccane-Derived Diterpenoid with Potent PPAR-γ Agonistic Activity from Alternaria brassicicola

Li, F., Sun, W., Guan, J., Lu, Y., Zhang, S., Lin, S. J., Liu, J., Gao, W., Wang, J., Hu, Z., et al. (2018) · Organic Letters · doi:10.1021/acs.orglett.8b03553 · Cited by 41 · see citing works

Role of Peroxisome Proliferator-Activated Receptor γ in Ocular Diseases

Zhang, S., Gu, H., & Hu, N. (2015) · Journal of Ophthalmology · doi:10.1155/2015/275435 · Cited by 40 · see citing works

Variation in Association Between Thiazolidinediones and Heart Failure Across Ethnic Groups: Retrospective analysis of Large Healthcare Claims Databases in Six Countries

Roughead, E. E., Chan, E. W., Choi, N., Kimura, M., Kimura, T., Kubota, K., Lai, E. C., Man, K. K. C., Nguyen, T. A., Ooba, N., et al. (2015) · Drug Safety · doi:10.1007/s40264-015-0318-4 · Cited by 40 · see citing works

Clozapine modifies the differentiation program of human adipocytes inducing browning

Kristóf, E., Doan-Xuan, Q.-M., Sárvári, A., Klusóczki, Á., Fischer-Posovszky, P., Wabitsch, M., Bacsó, Z., Bai, P., Balajthy, Z., & Fésüs, L. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.230 · Cited by 36 · see citing works

PPARγ and Its Agonists in Chronic Kidney Disease

Ma, Y., Shi, M., Wang, Y., & Liu, J. (2020) · International Journal of Nephrology · doi:10.1155/2020/2917474 · Cited by 39 · see citing works

Obesity, diabetes, and cancer: epidemiology, pathophysiology, and potential interventions

Mesquita, L. D. A., Wayerbacher, L. F., Schwartsmann, G., & Gerchman, F. (2023) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000647 · Cited by 41 · see citing works

Effects and molecular mechanisms of the antidiabetic fraction of Acorus calamus L. on GLP-1 expression and secretion in vivo and in vitro

Liu, Y., Si, M., Lü, W., Zhang, L., Zhou, C., Deng, S., & Wu, H. (2015) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2015.03.014 · Cited by 37 · see citing works

Chemical Crosslinking Mass Spectrometry Reveals the Conformational Landscape of the Activation Helix of PPARγ; a Model for Ligand-Dependent Antagonism

Zheng, J., Corzo, C. A., Chang, M. R., Shang, J., Lam, V. Q., Brust, R., Blayo, A., Bruning, J. B., Kamenecka, T. M., Kojetin, D. J., et al. (2018) · Structure · doi:10.1016/j.str.2018.07.007 · Cited by 36 · see citing works

Outcomes and lessons from the PROactive study

Scheen, A. J. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.09.001 · Cited by 35 · see citing works

NPY1R-targeted peptide-mediated delivery of a dual PPARα/γ agonist to adipocytes enhances adipogenesis and prevents diabetes progression

Wittrisch, S., Klöting, N., Mörl, K., Chakaroun, R., Blüher, M., & Beck‐Sickinger, A. G. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.11.009 · Cited by 34 · see citing works

Stabilization of high-risk plaques

Takata, K., Imaizumi, S., Zhang, B., Miura, S., & Saku, K. (2016) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2015.10.03 · Cited by 38 · see citing works

Pioglitazone increases the glycolytic efficiency of human Sertoli cells with possible implications for spermatogenesis

Meneses, M. J., Bernardino, R. L., Sá, R., Silva, J., Barros, A., Sousa, M., Silva, B. M., Oliveira, P. F., & Alves, M. G. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.08.011 · Cited by 34 · see citing works

Atherosclerosis: Conventional intake of cardiovascular drugs versus delivery using nanotechnology – A new chance for causative therapy?

Groner, J., Göpferich, A. M., & Breunig, M. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.03.034 · Cited by 34 · see citing works

A polyphenol-rich prebiotic in combination with a novel probiotic formulation alleviates markers of obesity and diabetes in Drosophila

Westfall, S., Lomis, N., & Prakash, S. (2018) · Journal of Functional Foods · doi:10.1016/j.jff.2018.07.012 · Cited by 33 · see citing works

Pharmacological activation of peroxisome proliferator‐activated receptor γ (PPAR‐γ) protects against hypoxia‐associated fetal growth restriction

Lane, S. L., Dodson, R. B., Doyle, A. S., Park, H., Rathi, H., Matarrazo, C. J., MOORE, L. G., Lorca, R. A., Wolfson, G. H., & Julian, C. G. (2019) · The FASEB Journal · doi:10.1096/fj.201900214r · Cited by 32 · see citing works

Hydroxy-α-sanshool from the fruits of Zanthoxylum bungeanum Maxim. promotes browning of white fat by activating TRPV1 to induce PPAR-γ deacetylation

Zhang, Q., He, C., Wang, L., Qian, D., Tang, D., Jiang, S., Chen, W., Wu, C., & Peng, W. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155113 · Cited by 31 · see citing works

Design, Synthesis, and Biological Evaluation of Indole Biphenylcarboxylic Acids as PPARγ Antagonists

Asteian, A., Blayo, A., He, Y., Koenig, M., Shin, Y., Kuruvilla, D. S., Corzo, C. A., Cameron, M. D., Li, L., Ruiz, C. H., et al. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00218 · Cited by 31 · see citing works

Rosiglitazone Promotes AQP2 Plasma Membrane Expression In Renal Cells Via a Ca2+-Dependent/cAMP-Independent Mechanism

Procino, G., Gerbino, A., Milano, S., Nicoletti, M. C., Mastrofrancesco, L., Carmosino, M., & Svelto, M. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373933 · Cited by 30 · see citing works

A role for Peroxisome Proliferator-Activated Receptor Beta in T cell development

Mothe‐Satney, I., Murdaca, J., Sibille, B., Rousseau, A., Squillace, R., Menn, G. L., Rekima, A., Larbret, F., Pelé, J., Verhasselt, V., et al. (2016) · Scientific Reports · doi:10.1038/srep34317 · Cited by 30 · see citing works

The perceptions of natural compounds against dipeptidyl peptidase 4 in diabetes: from in silico to in vivo

Lin, S., Chang, C., Tsai, M., Cheng, H., Chen, J.-C., Leong, M. K., & Weng, C. (2019) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622319875305 · Cited by 29 · see citing works

Soluble (pro)renin receptor treats metabolic syndrome in mice with diet-induced obesity via interaction with PPARγ

Wang, F., Luo, R., Zou, C., Xie, S., Peng, K., Zhao, L., Yang, K., Xu, C., & Yang, T. (2020) · JCI Insight · doi:10.1172/jci.insight.128061 · Cited by 29 · see citing works

Post-pancreatitis diabetes mellitus: insight on optimal management with nutrition and lifestyle approaches

Singh, A., Aggarwal, M., Garg, R., Stevens, T., & Chahal, P. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2090601 · Cited by 30 · see citing works

In vitro evaluation of dual agonists for PPARγ/β from the flower of Edgeworthia gardneri (wall.) Meisn

Gao, D., Zhang, Y.-L., Xu, P., Lin, Y., Yang, F. Q., Liu, J., Zhu, H.-W., & Xia, Z. (2015) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2014.12.034 · Cited by 28 · see citing works

Complications of Diabetes Mellitus

Brownlee, M., Aiello, L. P., Cooper, M. E., Vinik, A. I., Plutzky, J., & Boulton, A. J. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00033-2 · Cited by 29 · see citing works

Antrodia cinnamomea and its compound dehydroeburicoic acid attenuate nonalcoholic fatty liver disease by upregulating ALDH2 activity

Cao, Y., Yue, S.-S., Wang, A.-Y., Xu, L., Hu, Y., Qiao, X., Wu, T., Ye, M., Wu, Y., & Qi, R. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115146 · Cited by 26 · see citing works

Use of pioglitazone in the treatment of diabetes: effect on cardiovascular risk

Hu, H., & Zou (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s34421 · Cited by 26 · see citing works

Hypoglycemic Activity through a Novel Combination of Fruiting Body and Mycelia ofCordyceps militarisin High-Fat Diet-Induced Type 2 Diabetes Mellitus Mice

Yu, S.-H., Chen, S.-Y. T., Li, W.-S., Dubey, N. K., Chen, W.-H., Chuu, J., Leu, S., & Deng, W. (2015) · Journal of Diabetes Research · doi:10.1155/2015/723190 · Cited by 26 · see citing works

Current clinical evidence on pioglitazone pharmacogenomics

Kawaguchi‐Suzuki, M., & Frye, R. F. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00147 · Cited by 25 · see citing works

Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years

Norwood, P., Liutkus, J. F., Haber, H., Pintilei, E., Boardman, M. K., & Trautmann, M. E. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.09.007 · Cited by 24 · see citing works

Identification of an allosteric hotspot for additive activation of PPARγ in antidiabetic effects

Li, F., Lu, S., Zheng, Z., Chen, Y., Zhao, Y., Song, K., Xue, H., Jin, L., Li, Y., Huang, C., et al. (2021) · 中国科学通报：英文版 · doi:10.1016/j.scib.2021.01.023 · Cited by 24 · see citing works

Racial ethnic differences in type 2 diabetes treatment patterns and glycaemic control in the Boston Area Community Health Survey

Goonesekera, S. D., YANG, M. H., Hall, S. A., Fang, S. C., Piccolo, R. S., & McKinlay, J. B. (2015) · BMJ Open · doi:10.1136/bmjopen-2014-007375 · Cited by 24 · see citing works

Increased susceptibility of db/db mice to rosiglitazone-induced plasma volume expansion: role of dysregulation of renal water transporters

Zhou, L., Liu, G., Jia, Z., Yang, K., Sun, Y., Kakizoe, Y., Liu, M., Zhou, S., Chen, R., Yang, B., et al. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00004.2013 · Cited by 24 · see citing works

Metformin‐induced mitochondrial function and ABCD 2 up‐regulation in X‐linked adrenoleukodystrophy involves AMP ‐activated protein kinase

Singh, J., Olle, B., Suhail, H., Felicella, M. M., & Giri, S. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13562 · Cited by 24 · see citing works

Inhibition of Grb14, a negative modulator of insulin signaling, improves glucose homeostasis without causing cardiac dysfunction

Ding, X., Iyer, R. P., Novotny, C. A., Metzger, D., Zhou, H. H., Smith, G. I., Yoshino, M., Yoshino, J., Klein, S., Swaminath, G., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-60290-1 · Cited by 24 · see citing works

A systems biology approach to understand the pathophysiological mechanisms of cardiac pathological hypertrophy associated with rosiglitazone

Verschuren, L., Wielinga, P. Y., Kelder, T., Radonjić, M., Salic, K., Kleemann, R., van Ommen, B., & Kooistra, T. (2014) · BMC Medical Genomics · doi:10.1186/1755-8794-7-35 · Cited by 22 · see citing works

Endoscopic management of weight regain following Roux-en-Y gastric bypass

de Moura, D. T. H., & Thompson, C. C. (2019) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2019.1571907 · Cited by 22 · see citing works

Integrating in vitro testing and physiologically-based pharmacokinetic (PBPK) modelling for chemical liver toxicity assessment—A case study of troglitazone

Yu, L. C., Li, H., Zhang, C., Zhang, Q., Guo, J., Li, J., Yuan, H., Li, L., Carmichael, P. L., & Peng, S. (2019) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2019.103296 · Cited by 20 · see citing works

Thiazolidinediones were associated with higher risk of cardiovascular events in patients with type 2 diabetes and cirrhosis

Yen, F., Wei, J. C., Chiu, L., Hsu, C., Hou, M., & Hwu, C. (2020) · Liver International · doi:10.1111/liv.14714 · Cited by 20 · see citing works

Discovery of 2-deoxy glucose surfaced mixed layer dendrimer: a smart neuron targeted systemic drug delivery system for brain diseases

Dhull, A., Zhang, Z. L., Sharma, R. B., Dar, A. I., Rani, A., Wei, J., Gopalakrishnan, S., Ghannam, A., Hahn, V., Pulukuri, A. J., et al. (2024) · Theranostics · doi:10.7150/thno.95476 · Cited by 20 · see citing works

Is the Mouse a Good Model of Human PPARγ-Related Metabolic Diseases?

Pap, A., Cuaranta‐Monroy, I., Peloquin, M., & Nagy, L. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17081236 · Cited by 20 · see citing works

Pioglitazone treatment and cardiovascular event and death in subjects with type 2 diabetes without established cardiovascular disease (JDDM 36)

Yokoyama, H., Araki, S., Kawai, K., Hirao, K., Oishi, M., Sugimoto, K., Sone, H., Maegawa, H., & Kashiwagi, A. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.06.005 · Cited by 19 · see citing works

The safety of thiazolidinediones

Tolman, K. G. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.534982 · Cited by 53 · see citing works

Thiazolidinediones: the forgotten diabetes medications

Lebovitz, H. E. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1270-y · Cited by 388 · see citing works

The current role of thiazolidinediones in diabetes management

Rizos, C. V., Kei, A. A., & Elisaf, M. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1737-4 · Cited by 70 · see citing works

Thiazolidinediones☆

Bailey, C. J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.10867-0 · Cited by 2 · see citing works

Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future

Davidson, M., Mattison, D. R., Azoulay, L., & Krewski, D. R. (2017) · Critical Reviews in Toxicology · doi:10.1080/10408444.2017.1351420 · Cited by 114 · see citing works